ABSTRACT
Management of feline chronic gastroenteropathies has included intervention with both veterinary therapeutic formulas designed to manage non-specific gastrointestinal disorders and those designed with limited novel or hydrolyzed ingredients for management of food-responsive enteropathies and steroid-responsive enteropathies (inflammatory bowel disease). There have been few studies evaluating the use of dietary intervention for the management of feline chronic gastroenteropathy. This prospective, multi-center study evaluated the use of two commercially available feline veterinary therapeutic dry diets designed to manage non-specific gastrointestinal disorders in 28 cats with a history of chronic vomiting and/or diarrhea. The majority of cats enrolled in the study had a history of vomiting (n = 25), with a smaller number having a history of concurrent diarrhea (n = 2) or diarrhea alone (n = 3). Cats were excluded if diagnostic tests identified any systemic or infectious disease that could be associated with the clinical signs of vomiting or diarrhea, and if they were panhypoproteinemic, hypoalbuminemic, hypocobalaminemic, or had a Spec fPL ≥5.4 µg/L. Cats were randomized to one of two veterinary therapeutic diets for 4 weeks. Feeding of both therapeutic diets resulted in a numeric reduction in the number of vomiting episodes over the 4-week period, but no significant differences were seen between dietary interventions. When looking within dietary groups, significant differences were seen in cats fed Diet A with reductions of 69.1, 73.3, and 63.2% (p values of 0.008, 0.003, and 0.029) in weeks 2, 3, and 4, respectively, when compared to week 0. The probability of vomiting also showed significant reductions in cats fed Diet A between weeks 0 and 2, 3, and 4, with odds ratios of 0.008, 0.005, and 0.005, respectively (p values of 0.038, 0.23, and 0.23). Results of this study demonstrate that a veterinary therapeutic gastrointestinal formula can be effective in the management of feline chronic vomiting. Cats that fail to respond to this dietary approach after a 2- to 4-week trial may benefit from a limited novel or hydrolyzed ingredient formula and may require additional diagnostics to better characterize the underlying disease.
ABSTRACT
OBJECTIVES: The aims of the study were to define factors that owners consider relevant to the health-related quality of life (HRQoL) of cats, to develop an instrument based on this information, and to evaluate the validity and reliability of the final instrument (the Cat HEalth and Wellbeing [CHEW] Questionnaire). METHODS: Psychometric research techniques and guidance from the US Food and Drug Administration on outcome measures were used to develop a valid and reliable instrument. Fifty-four cat owners and caregivers participated in the qualitative research, while 1303 cat owners were included in the quantitative validation phase (development dataset, n = 648; validation dataset, n = 655). A random subset of cat owners (n = 391) also participated in test-retest evaluation. Qualitative research was used to generate a draft instrument, which was then subjected to quantitative validation techniques. These included item reduction, domain identification, data quality assessment, and exploratory and confirmatory analysis to develop a final instrument, which underwent confirmatory reliability and validity assessment. RESULTS: A draft instrument with 11 domains and 100 items based on qualitative research underwent online quantitative validation testing which refined the instrument to eight domains and 33 items. Confirmatory reliability and validity assessment showed that the final instrument had good validity, was able to discriminate between cats by age and overall health status, and demonstrated good internal and test-retest reliability. CONCLUSIONS AND RELEVANCE: The CHEW Questionnaire was developed and validated. Additional research is needed to verify its ability to differentiate cats with and without disease, and to assess its potential as a screening tool.
Subject(s)
Cat Diseases/diagnosis , Animals , Cats , Health Status , Quality of Life , Reproducibility of Results , Surveys and QuestionnairesABSTRACT
Women who self-report symptoms of overactive bladder (OAB), including nocturia, experience significant sleep deficits and a diminished quality of life. These deficits and their impacts are greater among women who awaken two or more times per night. When evaluating patients with OAB, it is important for clinicians to assess sleep habits and practices in addition to bladder symptoms to fully gauge the health and well-being of women with OAB.
Subject(s)
Health Surveys , Sleep Wake Disorders/etiology , Urinary Bladder, Overactive/complications , Adult , Aged , Female , Humans , Middle Aged , Quality of Life , Sleep Wake Disorders/nursing , Sleep Wake Disorders/psychology , Urinary Bladder, Overactive/nursing , Urinary Bladder, Overactive/psychologyABSTRACT
INTRODUCTION: Insufficient documentation exists regarding the prevalence of hypoactive sexual desire disorder (HSDD) in surgically menopausal (SM) women in European countries. Women who have undergone hysterectomy and bilateral oophorectomy experience a loss of ovarian hormones. Inclusion of these women in an epidemiological study provided the opportunity to study biological and cultural impacts on sexual function. AIM: The aim of this study was to compare the prevalence of HSDD among SM women in France, Germany, Italy, and the United Kingdom, as well as the relationship between low sexual desire and sexual activity or behavior, and sexual or partner relationship satisfaction. METHODS: Cross-sectional survey of a convenience sample of 427 SM women aged 20-70 years. Main Outcome Measures. The desire domain of the Profile of Female Sexual Function (PFSF) to identify women with low sexual desire, Personal Distress Scale (PDS) to measure distress caused by low sexual desire, and a sexual activities measure. Women with low sexual desire who were distressed were classified as having HSDD. RESULTS: SM women having low sexual desire ranged from 35% (United Kingdom) to 44% (Italy); of these women, 16% (Germany) to 56% (France) were distressed because of their low sexual desire. Overall, SM women classified with HSDD ranged from 7% (Germany) to 22% (France). A strong positive correlation was observed between sexual desire and arousal, orgasm, and sexual pleasure in all countries (P < 0.001). Low sexual desire leads to less sexual activity, more dissatisfaction with sex life and partner relationship, and more negative emotional or psychological states, than normal desire in each country. CONCLUSIONS: A similar percentage of SM women with low sexual desire were found across countries suggesting the role of biological factors (i.e., losing ovarian hormones) in determining sexual desire. Differences in the percentage of SM women with HSDD suggest a role for cultural factors in determining how low sexual desire is perceived.
Subject(s)
Ovariectomy/adverse effects , Postmenopause , Sexual Dysfunctions, Psychological/epidemiology , Adult , Aged , Analysis of Variance , Confidence Intervals , Cross-Sectional Studies , Epidemiologic Studies , Europe/epidemiology , Female , Health Surveys , Humans , Middle Aged , Odds Ratio , Ovariectomy/methods , Prevalence , Psychometrics , Risk Factors , Sexual Dysfunctions, Psychological/etiology , Surveys and QuestionnairesABSTRACT
INTRODUCTION: Transdermal testosterone patch (TTP) treatment produced statistically significant improvements in a satisfying sexual activity (SSA), sexual desire, and personal distress in postmenopausal women suffering from hypoactive sexual desire disorder (HSDD), but clinical significance of these changes was not determined. AIM: To quantify the magnitude of change in three principal outcomes measures determined by HSDD patients as associated with the perception of meaningful benefit with TTP therapy. METHODS: The criteria for defining responders were determined using anchoring methodology and receiver operating characteristics analysis to establish minimum important differences (MIDs) in a representative subsample of 132 patients in two randomized, controlled trials in surgically menopausal women with HSDD (N = 1,094). Perceived benefit was established based upon the question "Overall, would you say that you experienced a meaningful benefit from the study patches?". These data defined responders and established MIDs for changes in sexual desire, SSA, and personal distress. The MIDs were applied to the two trials to establish responder rates in each treatment group. MAIN OUTCOME MEASURES: Changes in score that correspond to the MID for sexual desire, SSA, and personal distress, and responder rates in each treatment group based upon these values. RESULTS: Increases in frequency of SSA of greater than 1 activity/4 weeks, increases in sexual desire score of > or = 8.9, and decreases in the personal distress score of > or = 20.0 were identified as threshold improvements best able to differentiate responders and nonresponders. The responder rate was significantly higher (P < 0.001) in the testosterone group vs. placebo for all three outcomes measures (sexual desire, 50% vs. 34%; SSA, 44% vs. 30%; personal distress, 51% vs. 39%). CONCLUSIONS: Changes in sexual desire, SSA, and personal distress observed with TTP treatment in surgically menopausal women with HSDD were clinically significant and were associated with a meaningful treatment benefit.
Subject(s)
Depression/diagnosis , Depression/epidemiology , Postmenopause/psychology , Sexual Behavior/psychology , Sexual Dysfunctions, Psychological/epidemiology , Surveys and Questionnaires , Administration, Cutaneous , Administration, Topical , Depression/psychology , Double-Blind Method , Female , Humans , Middle Aged , Ovariectomy , Personal Satisfaction , ROC Curve , Sexual Dysfunctions, Psychological/diagnosis , Sexual Dysfunctions, Psychological/therapy , Testosterone/therapeutic useABSTRACT
INTRODUCTION: A range of methodological inconsistencies has the potential to affect reported prevalence rates of sexual intercourse. AIMS: We reviewed published studies of sexual intercourse frequency reported by women and associated factors. METHODS: Literature search of electronic databases. Inclusion criteria for selected cross-sectional studies were population and community-based studies of frequency of intercourse in women published in English or German languages with sample size greater than 300. Longitudinal studies were selected if duration was at least 1 year and samples were not clinically based. MAIN OUTCOME MEASURES: Frequency of sexual intercourse/activities and any associated factors. RESULTS: There was a great deal of variation in the mean frequency of intercourse across all age groups with higher rates reported by European and American women. There was a reduction in frequency of sexual intercourse from age 50 among women from Europe and the United States. Asian women reported increasing rates through the age group 20-30 followed by a decline. Change with age was not as evident among African and South American studies. Factors most often associated with the frequency of sexual intercourse were age, parity, duration of relationship, pregnancy, time, relationship status, fertility intentions, and contraception. CONCLUSIONS: There is variation in reported frequency of sexual intercourse between studies, age groups, and continents. Some of the variation may be due to variation in definitions, study designs, and methods suggesting a need for greater consistency in research practice.
Subject(s)
Attitude to Health/ethnology , Coitus , Population Surveillance/methods , Sexual Behavior/classification , Sexual Behavior/ethnology , Adult , Age Distribution , Aged , Contraception Behavior/statistics & numerical data , Cross-Sectional Studies , Cultural Characteristics , Female , Global Health , Humans , Life Style , Longitudinal Studies , Middle Aged , Regression Analysis , Research Design , Sexual Behavior/statistics & numerical data , Sexual PartnersABSTRACT
OBJECTIVES: To determine patterns of symptoms across age groups, identify symptom groups associated with ovarian hormonal depletion or other variables, and develop a prediction model for each symptom. DESIGN: This was a cross-sectional survey of 4,517 women ages 20 to 70 years recruited from market research panels in the United States, United Kingdom, Germany, France, and Italy using a self-report questionnaire that included general health information and a checklist of 36 symptoms. Stepwise regression was used to determine for each symptom how prevalence varied with age, indicators of menopausal hormonal changes, and the effects of other explanatory variables, including body mass index, morbidity, and country. Hierarchical clustering was used to group symptoms. RESULTS: Six groups of symptoms were found, of which two groups, with seven symptoms in total, were related to markers of menopausal hormonal change: a group consisting of hot flashes and night sweats and a second group including poor memory; difficulty sleeping; aches in the neck, head, and shoulders; vaginal dryness; and difficulty with sexual arousal. Physical and mental morbidity affected estimates of the prevalence of all symptoms. Psychological symptoms declined with age from a maximum prevalence before age 40. Certain physical symptoms increased with age and body mass index. Clustering identified three country groups: (1) US and UK women; (2) French and Italian women; and (3) German women. There were marked differences in prevalence between countries for certain physical and psychological symptoms. CONCLUSIONS: The seven symptoms most linked to menopausal hormonal change should form part of any future menopause symptom list. Physical and mental morbidity affect symptom prevalence and should be measured.
Subject(s)
Cross-Cultural Comparison , Hot Flashes/epidemiology , Sleep Wake Disorders/epidemiology , Adult , Aged , Aging , Cross-Sectional Studies , Europe/epidemiology , Europe/ethnology , Female , Hot Flashes/ethnology , Hot Flashes/etiology , Humans , Menopause , Middle Aged , Prevalence , Sleep Wake Disorders/ethnology , Sleep Wake Disorders/etiology , Surveys and Questionnaires , United Kingdom/epidemiology , United Kingdom/ethnology , United States/epidemiology , United States/ethnologyABSTRACT
OBJECTIVE: Explore the association between Hypoactive Sexual Desire Disorder (HSDD) and aging. The American Foundation of Urologic Disease and the American Psychiatric Association stipulate that HSDD is only diagnosed when both low sexual desire and sexually related personal distress are present. DESIGN: Community-based, cross-sectional study. SETTING: Europe (UK, Germany, France, Italy) and the USA. PATIENT(S): Women aged 20-70 in sexual relationships participating in the Women's International Study of Health and Sexuality (n=1998 Europe, n=1591 USA). INTERVENTION(S): No interventions were administered. MAIN OUTCOME MEASURES: Self-administered questionnaire that included two validated instruments: Profile of Female Sexual Function(c) measured sexual desire; Personal Distress Scale(c) measured sexual distress. Women with low desire and distress were considered to have HSDD. RESULTS: The proportion of European women with low desire increased from 11% amongst women aged 20-29 years to 53% amongst women aged 60-70 years. The proportion of American women with low desire displayed a trend towards an increase with age. In the 20-29 year age group 65% of European women and 67% of American women with low sexual desire were distressed by it. This decreased to 22% and 37%, respectively, in the 60-70 year age group. In Europe and the USA the prevalence of HSDD in the population did not change significantly with age (6-13% in Europe, 12-19% in the USA). CONCLUSIONS: The proportion of women with low desire increased with age while the proportion of women distressed about their low desire decreased with age. Consequently, the prevalence of HSDD remained essentially constant with age. This may explain why no association between HSDD and age is often reported in the literature.
Subject(s)
Risk Assessment/methods , Sexual Dysfunctions, Psychological/epidemiology , Stress, Psychological/epidemiology , Adult , Age Distribution , Aged , Comorbidity , Europe/epidemiology , Female , Humans , Middle Aged , Risk Factors , Statistics as Topic , United States/epidemiologyABSTRACT
OBJECTIVE: To determine the prevalence of hypoactive sexual desire disorder (HSDD) among US women by reproductive status and age and to explore the correlates of sexually related distress. DESIGN: The Women's International Study on Health and Sexuality questionnaire was mailed to a national sample of US women in 2000. The survey included validated questionnaires: the Short Form-36, which measures overall health status; the Profile of Female Sexual Function, which assesses sexual desire; and the Personal Distress Scale, which measures distress caused by low desire. Four groups of women were studied: surgically postmenopausal, aged 20 to 49 years and 50 to 70 years; premenopausal, aged 20 to 49 years; and naturally postmenopausal, aged 50 to 70 years. Clinically derived cutoff Profile of Female Sexual Function and Personal Distress Scale scores were used to classify women with HSDD and determine its prevalence. The relations between sexual desire and frequency of sexual activity or relationship satisfaction were assessed. Overall health status of HSDD women and women with normal desire were compared. RESULTS: The prevalence of HSDD ranged from 9% in naturally postmenopausal women to 26% in younger surgically postmenopausal women. The prevalence of HSDD was significantly greater among surgically postmenopausal women, aged 20 to 49 years, than premenopausal women of similar age, whereas there were no significant differences in the prevalence between surgically postmenopausal women, aged 50 to 70 years, and naturally postmenopausal women. For many women, HSDD was associated with emotional and psychological distress as well as significantly lower sexual and partner satisfaction. HSDD was also associated with significant decrements in general health status, including aspects of mental and physical health. CONCLUSIONS: HSDD is prevalent among women at all reproductive stages, with younger surgically postmenopausal women at greater risk, and is associated with a less active sex life and decreased sexual and relationship satisfaction.